Sugi Predict

Sugi Predict / Compounds / SCHEMBL1906288

SCHEMBL1906288

SCHEMBL1906288

O=P(O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(S)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 7/20 0.74
▸ P2RX3 P56373 6/20 0.74
▸ P2RX2 Q9UBL9 6/20 0.74
▸ P2RY2 P41231 3/20 0.74
▸ P2RX4 Q99571 2/20 0.74
▸ P2RX1 P51575 2/20 0.74
▸ SRC P12931 2/20 0.74
▸ SMN1; SMN2 Q16637 2/20 0.74
▸ ALDH1A1 P00352 1/20 0.74
▸ RNASEL Q05823 1/20 0.71
▸ TRPM2 O94759 2/20 0.69
▸ MACROD2 A1Z1Q3 1/20 0.69
▸ SIRT6 Q8N6T7 1/20 0.69
▸ MACROD1 Q9BQ69 1/20 0.69
▸ GPR17 Q13304 1/20 0.69
▸ DNPH1 O43598 1/20 0.65
▸ PRKAB2 O43741 1/20 0.65
▸ LDHA P00338 1/20 0.65
▸ ADRB2 P07550 1/20 0.65
▸ FBP1 P09467 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1906291 1.00 P2RY1 (0.74) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL1905822 0.99 P2RX3 (0.72) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL1905818 0.99 P2RX3 (0.72) P2RY1P2RX3P2RX2P2RY2P2RX4
Thioinosine Monophosphate SCHEMBL29746215 0.91 DNPH1 (0.77) P2RY1P2RX3P2RX2P2RY2P2RX4
Thioinosine Monophosphate SCHEMBL379365 0.91 DNPH1 (0.77) P2RY1P2RX3P2RX2P2RY2P2RX4
Thioinosine Monophosphate SCHEMBL15810629 0.91 DNPH1 (0.77) P2RY1P2RX3P2RX2P2RY2P2RX4
Thioinosine Monophosphate SCHEMBL379366 0.91 DNPH1 (0.77) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL3862068 0.90 P2RX3 (0.61) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL5365040 0.89 P2RY1 (0.75) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL3859612 0.89 P2RY1 (0.67) P2RY1P2RX3P2RX2P2RY2P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140170689-A1 Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2014-06-19 — — US claimed
US-12485171-B2 Methods of disease activity profiling for personalized therapy management PROMETHEUS LABORATORIES INC. (US) 2025-12-02 — — US disclosed
US-20230078652-A1 METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION PROMETHEUS LABORATORIES INC (US) 2023-03-16 — — US disclosed
US-11435347-B2 Methods for prediction of anti-TNF α drug levels and autoantibody formation PROMETHEUS LABORATORIES INC. (US) 2022-09-06 — — US disclosed
US-20220096629-A1 METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT PROMETHEUS LABORATORIES INC. 2022-03-31 — — US disclosed
US-11219895-B2 Blood analysis cartridge KING ABDULAZIZ UNIVERSITY (SA) 2022-01-11 — — US disclosed
US-11160863-B2 Methods of disease activity profiling for personalized therapy management PROMETHEUS LABORATORIES INC. (US) 2021-11-02 — — US disclosed
US-20210308674-A1 BLOOD ANALYSIS CARTRIDGE KING ABDULAZIZ UNIVERSITY (SA) 2021-10-07 — — US disclosed
US-20210001333-A1 MICROFLUIDIC DEVICE FOR MEASURING THE ENZYMATIC ACTIVITY OF THIOPURIN S-METHYLTRANSFERASE KING ABDULAZIZ UNIVERSITY (SA) 2021-01-07 — — US disclosed
US-10794906-B2 Assays for detecting neutralizing autoantibodies to biologic therapy PROMETHEUS BIOSCIENCES, INC. (US) 2020-10-06 — — US disclosed
EP-2494352-A1 ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES Prometheus Laboratories Inc. (US) 2012-09-05 — — EP disclosed
WO-2012054532-A1 METHODS FOR DETERMINING ANTI-DRUG ANTIBODY ISOTYPES PROMETHEUS LABORATORIES INC. (US) 2012-04-26 — — WO disclosed
US-20110189664-A1 DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT UNIVERSITY OF WOLLONGONG 2011-08-04 — — US disclosed
US-7972780-B2 Inosine triphosphate pyrophosphatase (ITPase); predicting tolerance to a thiopurine drug via genotyping; for chronic inflammatory disease and haematological malignancy GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST (GB) 2011-07-05 — — US disclosed
WO-2011056590-A1 ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES PROMETHEUS LABORATORIES INC. (US) 2011-05-12 — — WO disclosed
US-20090286696-A1 Double-Stranded Olidonucleotides and Uses Therefor UNIVERSITY OF WOLLONGONG 2009-11-19 — — US disclosed
WO-2008148143-A1 DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT UNIVERSITY OF WOLLONGONG (AU) 2008-12-11 — — WO disclosed
WO-2006081623-A1 DOUBLE-STRANDED OLIGONUCLEOTIDES AND USES THEREFOR THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2006-08-10 — — WO disclosed
US-20050202483-A1 ITPase gene polymorphisms associated with adverse durg reactions to azathioprine therapy GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST (GB) 2005-09-15 — — US disclosed
WO-2005078125-A2 ITPASE GENE POLYMORPHISMS ASSOCIATED WITH ADVERSE DRUG REACTIONS TO AZATHIOPRINE THERAPY GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST (GB) 2005-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286696-A1 Double-Stranded Olidonucleotides and Uses Therefor DNTT, ADAR, DUT P2RY1 3678/4885P2RX3 2467/4885P2RX2 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.